An oral supplement enriched with fish oil, soluble fiber, and antioxidants for corticosteroid sparing in ulcerative colitis: A randomized, controlled trial
Background & Aims : N-3 fatty acids from fish oil, antioxidants, and short-chain fatty acids (SCFAs) produced during the fermentation of soluble fiber may attenuate inflammation associated with ulcerative colitis (UC). We assessed the efficacy of a nutritionally balanced oral supplement enriched...
Gespeichert in:
Veröffentlicht in: | Clinical gastroenterology and hepatology 2005-04, Vol.3 (4), p.358-369 |
---|---|
Hauptverfasser: | , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 369 |
---|---|
container_issue | 4 |
container_start_page | 358 |
container_title | Clinical gastroenterology and hepatology |
container_volume | 3 |
creator | Seidner, Douglas L. Lashner, Bret A. Brzezinski, Aaron Banks, Phillip L.C. Goldblum, John Fiocchi, Claudio Katz, Jeffry Lichtenstein, Gary R. Anton, Peter A. Kam, Lori Y. Garleb, Keith A. Demichele, Stephen J. |
description | Background & Aims
: N-3 fatty acids from fish oil, antioxidants, and short-chain fatty acids (SCFAs) produced during the fermentation of soluble fiber may attenuate inflammation associated with ulcerative colitis (UC). We assessed the efficacy of a nutritionally balanced oral supplement enriched with fish oil, fructooligosaccharides, gum arabic, vitamin E, vitamin C, and selenium on disease activity and medication use in adults with mild to moderate UC.
Methods
: A total of 121 patients with UC and a disease activity index (DAI) from 3–9 on a 12-point scale were block randomized for extent of disease and smoking status. In addition to their usual diet, patients consumed 18 oz of the oral supplement or a carbohydrate-based placebo formula each day for 6 months. Clinical and histologic responses were assessed at 3 and 6 months or at the final visit. A change in average prednisone use between groups was tested by using a linear mixed-effects model.
Results
: Eighty-six patients completed the study. Baseline characteristics were not different between groups except for a higher total DAI score in the oral supplement group (7.3 ± 1.3; n = 36) compared with the placebo group (6.2 ± 2.0; n = 50) (
P < .05). Both groups showed significant and similar degree of improvement at 6 months in DAI (−2.5 for oral supplement and −2.8 for placebo) and histologic index (−1.9 for oral supplement vs. −2.0 for placebo). Both intent-to-treat and completed patients given oral supplement had a significantly greater rate of decrease in the dose of prednisone required to control clinical symptoms over 6 months as compared with the placebo group (
P < .001).
Conclusions
: The improvement in clinical response combined with a decreased requirement for corticosteroids suggest that this enriched oral supplement can be a useful adjuvant therapy in patients with UC. |
doi_str_mv | 10.1016/S1542-3565(04)00672-X |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67721779</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S154235650400672X</els_id><sourcerecordid>67721779</sourcerecordid><originalsourceid>FETCH-LOGICAL-c410t-768f59a7b323747b638d049bb92ce970e3f6dde8986ff80036e1159f350ab4203</originalsourceid><addsrcrecordid>eNqFkcuKFTEQhhtRnIs-gpKVKJzWpDuddLuRwzBeYMCFCrML6aTiKUl32iQ9Xl7FlzXnAi5dFFX8fFU_yV9VTxh9ySgTrz6xjjd124nuOeUvKBWyqW_vVecHWUrG75_mPXJWXaT0jdJm4IN8WJ2xrm8aytl59Wc7kxC1J2ldFg8TzJnAHNHswJIfmHfEYdqRgH5DUvDr6KEoI8QN0bMtlTH8RFt6Ii5EYkLMaELKEANakhYdcf5KcCarNxB1xjsokMeM6TXZkliuhAl_g90Uec4xeF-cc0TtH1UPnPYJHp_6ZfXl7fXnq_f1zcd3H662N7XhjOZait51g5Zj27SSy1G0vaV8GMehMTBICq0T1kI_9MK5ntJWAGPd4NqO6pE3tL2snh3vLjF8XyFlNWEy4L2eIaxJCSkbJuVQwO4ImhhSiuDUEnHS8ZdiVO1TUYdU1P7LFeXqkIq6LXtPTwbrOIH9t3WKoQBvjgCUZ94hRJUMwmzAYgSTlQ34H4u_uyCfbA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67721779</pqid></control><display><type>article</type><title>An oral supplement enriched with fish oil, soluble fiber, and antioxidants for corticosteroid sparing in ulcerative colitis: A randomized, controlled trial</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Seidner, Douglas L. ; Lashner, Bret A. ; Brzezinski, Aaron ; Banks, Phillip L.C. ; Goldblum, John ; Fiocchi, Claudio ; Katz, Jeffry ; Lichtenstein, Gary R. ; Anton, Peter A. ; Kam, Lori Y. ; Garleb, Keith A. ; Demichele, Stephen J.</creator><creatorcontrib>Seidner, Douglas L. ; Lashner, Bret A. ; Brzezinski, Aaron ; Banks, Phillip L.C. ; Goldblum, John ; Fiocchi, Claudio ; Katz, Jeffry ; Lichtenstein, Gary R. ; Anton, Peter A. ; Kam, Lori Y. ; Garleb, Keith A. ; Demichele, Stephen J. ; The Enteral Nutrition in Ulcerative Colitis Study Group</creatorcontrib><description>Background & Aims
: N-3 fatty acids from fish oil, antioxidants, and short-chain fatty acids (SCFAs) produced during the fermentation of soluble fiber may attenuate inflammation associated with ulcerative colitis (UC). We assessed the efficacy of a nutritionally balanced oral supplement enriched with fish oil, fructooligosaccharides, gum arabic, vitamin E, vitamin C, and selenium on disease activity and medication use in adults with mild to moderate UC.
Methods
: A total of 121 patients with UC and a disease activity index (DAI) from 3–9 on a 12-point scale were block randomized for extent of disease and smoking status. In addition to their usual diet, patients consumed 18 oz of the oral supplement or a carbohydrate-based placebo formula each day for 6 months. Clinical and histologic responses were assessed at 3 and 6 months or at the final visit. A change in average prednisone use between groups was tested by using a linear mixed-effects model.
Results
: Eighty-six patients completed the study. Baseline characteristics were not different between groups except for a higher total DAI score in the oral supplement group (7.3 ± 1.3; n = 36) compared with the placebo group (6.2 ± 2.0; n = 50) (
P < .05). Both groups showed significant and similar degree of improvement at 6 months in DAI (−2.5 for oral supplement and −2.8 for placebo) and histologic index (−1.9 for oral supplement vs. −2.0 for placebo). Both intent-to-treat and completed patients given oral supplement had a significantly greater rate of decrease in the dose of prednisone required to control clinical symptoms over 6 months as compared with the placebo group (
P < .001).
Conclusions
: The improvement in clinical response combined with a decreased requirement for corticosteroids suggest that this enriched oral supplement can be a useful adjuvant therapy in patients with UC.</description><identifier>ISSN: 1542-3565</identifier><identifier>EISSN: 1542-7714</identifier><identifier>DOI: 10.1016/S1542-3565(04)00672-X</identifier><identifier>PMID: 15822041</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Administration, Oral ; Adrenal Cortex Hormones - administration & dosage ; Adult ; Antioxidants - therapeutic use ; Biopsy, Needle ; Colitis, Ulcerative - diet therapy ; Colitis, Ulcerative - pathology ; Dietary Fiber - administration & dosage ; Dietary Supplements ; Double-Blind Method ; Female ; Fish Oils - therapeutic use ; Follow-Up Studies ; Humans ; Immunohistochemistry ; Intestinal Mucosa - pathology ; Male ; Middle Aged ; Monitoring, Physiologic ; Probability ; Reference Values ; Risk Assessment ; Statistics, Nonparametric ; Treatment Outcome</subject><ispartof>Clinical gastroenterology and hepatology, 2005-04, Vol.3 (4), p.358-369</ispartof><rights>2005 American Gastroenterological Association</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c410t-768f59a7b323747b638d049bb92ce970e3f6dde8986ff80036e1159f350ab4203</citedby><cites>FETCH-LOGICAL-c410t-768f59a7b323747b638d049bb92ce970e3f6dde8986ff80036e1159f350ab4203</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S154235650400672X$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15822041$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Seidner, Douglas L.</creatorcontrib><creatorcontrib>Lashner, Bret A.</creatorcontrib><creatorcontrib>Brzezinski, Aaron</creatorcontrib><creatorcontrib>Banks, Phillip L.C.</creatorcontrib><creatorcontrib>Goldblum, John</creatorcontrib><creatorcontrib>Fiocchi, Claudio</creatorcontrib><creatorcontrib>Katz, Jeffry</creatorcontrib><creatorcontrib>Lichtenstein, Gary R.</creatorcontrib><creatorcontrib>Anton, Peter A.</creatorcontrib><creatorcontrib>Kam, Lori Y.</creatorcontrib><creatorcontrib>Garleb, Keith A.</creatorcontrib><creatorcontrib>Demichele, Stephen J.</creatorcontrib><creatorcontrib>The Enteral Nutrition in Ulcerative Colitis Study Group</creatorcontrib><title>An oral supplement enriched with fish oil, soluble fiber, and antioxidants for corticosteroid sparing in ulcerative colitis: A randomized, controlled trial</title><title>Clinical gastroenterology and hepatology</title><addtitle>Clin Gastroenterol Hepatol</addtitle><description>Background & Aims
: N-3 fatty acids from fish oil, antioxidants, and short-chain fatty acids (SCFAs) produced during the fermentation of soluble fiber may attenuate inflammation associated with ulcerative colitis (UC). We assessed the efficacy of a nutritionally balanced oral supplement enriched with fish oil, fructooligosaccharides, gum arabic, vitamin E, vitamin C, and selenium on disease activity and medication use in adults with mild to moderate UC.
Methods
: A total of 121 patients with UC and a disease activity index (DAI) from 3–9 on a 12-point scale were block randomized for extent of disease and smoking status. In addition to their usual diet, patients consumed 18 oz of the oral supplement or a carbohydrate-based placebo formula each day for 6 months. Clinical and histologic responses were assessed at 3 and 6 months or at the final visit. A change in average prednisone use between groups was tested by using a linear mixed-effects model.
Results
: Eighty-six patients completed the study. Baseline characteristics were not different between groups except for a higher total DAI score in the oral supplement group (7.3 ± 1.3; n = 36) compared with the placebo group (6.2 ± 2.0; n = 50) (
P < .05). Both groups showed significant and similar degree of improvement at 6 months in DAI (−2.5 for oral supplement and −2.8 for placebo) and histologic index (−1.9 for oral supplement vs. −2.0 for placebo). Both intent-to-treat and completed patients given oral supplement had a significantly greater rate of decrease in the dose of prednisone required to control clinical symptoms over 6 months as compared with the placebo group (
P < .001).
Conclusions
: The improvement in clinical response combined with a decreased requirement for corticosteroids suggest that this enriched oral supplement can be a useful adjuvant therapy in patients with UC.</description><subject>Administration, Oral</subject><subject>Adrenal Cortex Hormones - administration & dosage</subject><subject>Adult</subject><subject>Antioxidants - therapeutic use</subject><subject>Biopsy, Needle</subject><subject>Colitis, Ulcerative - diet therapy</subject><subject>Colitis, Ulcerative - pathology</subject><subject>Dietary Fiber - administration & dosage</subject><subject>Dietary Supplements</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Fish Oils - therapeutic use</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Intestinal Mucosa - pathology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Monitoring, Physiologic</subject><subject>Probability</subject><subject>Reference Values</subject><subject>Risk Assessment</subject><subject>Statistics, Nonparametric</subject><subject>Treatment Outcome</subject><issn>1542-3565</issn><issn>1542-7714</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkcuKFTEQhhtRnIs-gpKVKJzWpDuddLuRwzBeYMCFCrML6aTiKUl32iQ9Xl7FlzXnAi5dFFX8fFU_yV9VTxh9ySgTrz6xjjd124nuOeUvKBWyqW_vVecHWUrG75_mPXJWXaT0jdJm4IN8WJ2xrm8aytl59Wc7kxC1J2ldFg8TzJnAHNHswJIfmHfEYdqRgH5DUvDr6KEoI8QN0bMtlTH8RFt6Ii5EYkLMaELKEANakhYdcf5KcCarNxB1xjsokMeM6TXZkliuhAl_g90Uec4xeF-cc0TtH1UPnPYJHp_6ZfXl7fXnq_f1zcd3H662N7XhjOZait51g5Zj27SSy1G0vaV8GMehMTBICq0T1kI_9MK5ntJWAGPd4NqO6pE3tL2snh3vLjF8XyFlNWEy4L2eIaxJCSkbJuVQwO4ImhhSiuDUEnHS8ZdiVO1TUYdU1P7LFeXqkIq6LXtPTwbrOIH9t3WKoQBvjgCUZ94hRJUMwmzAYgSTlQ34H4u_uyCfbA</recordid><startdate>20050401</startdate><enddate>20050401</enddate><creator>Seidner, Douglas L.</creator><creator>Lashner, Bret A.</creator><creator>Brzezinski, Aaron</creator><creator>Banks, Phillip L.C.</creator><creator>Goldblum, John</creator><creator>Fiocchi, Claudio</creator><creator>Katz, Jeffry</creator><creator>Lichtenstein, Gary R.</creator><creator>Anton, Peter A.</creator><creator>Kam, Lori Y.</creator><creator>Garleb, Keith A.</creator><creator>Demichele, Stephen J.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20050401</creationdate><title>An oral supplement enriched with fish oil, soluble fiber, and antioxidants for corticosteroid sparing in ulcerative colitis: A randomized, controlled trial</title><author>Seidner, Douglas L. ; Lashner, Bret A. ; Brzezinski, Aaron ; Banks, Phillip L.C. ; Goldblum, John ; Fiocchi, Claudio ; Katz, Jeffry ; Lichtenstein, Gary R. ; Anton, Peter A. ; Kam, Lori Y. ; Garleb, Keith A. ; Demichele, Stephen J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c410t-768f59a7b323747b638d049bb92ce970e3f6dde8986ff80036e1159f350ab4203</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Administration, Oral</topic><topic>Adrenal Cortex Hormones - administration & dosage</topic><topic>Adult</topic><topic>Antioxidants - therapeutic use</topic><topic>Biopsy, Needle</topic><topic>Colitis, Ulcerative - diet therapy</topic><topic>Colitis, Ulcerative - pathology</topic><topic>Dietary Fiber - administration & dosage</topic><topic>Dietary Supplements</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Fish Oils - therapeutic use</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Intestinal Mucosa - pathology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Monitoring, Physiologic</topic><topic>Probability</topic><topic>Reference Values</topic><topic>Risk Assessment</topic><topic>Statistics, Nonparametric</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Seidner, Douglas L.</creatorcontrib><creatorcontrib>Lashner, Bret A.</creatorcontrib><creatorcontrib>Brzezinski, Aaron</creatorcontrib><creatorcontrib>Banks, Phillip L.C.</creatorcontrib><creatorcontrib>Goldblum, John</creatorcontrib><creatorcontrib>Fiocchi, Claudio</creatorcontrib><creatorcontrib>Katz, Jeffry</creatorcontrib><creatorcontrib>Lichtenstein, Gary R.</creatorcontrib><creatorcontrib>Anton, Peter A.</creatorcontrib><creatorcontrib>Kam, Lori Y.</creatorcontrib><creatorcontrib>Garleb, Keith A.</creatorcontrib><creatorcontrib>Demichele, Stephen J.</creatorcontrib><creatorcontrib>The Enteral Nutrition in Ulcerative Colitis Study Group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical gastroenterology and hepatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Seidner, Douglas L.</au><au>Lashner, Bret A.</au><au>Brzezinski, Aaron</au><au>Banks, Phillip L.C.</au><au>Goldblum, John</au><au>Fiocchi, Claudio</au><au>Katz, Jeffry</au><au>Lichtenstein, Gary R.</au><au>Anton, Peter A.</au><au>Kam, Lori Y.</au><au>Garleb, Keith A.</au><au>Demichele, Stephen J.</au><aucorp>The Enteral Nutrition in Ulcerative Colitis Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>An oral supplement enriched with fish oil, soluble fiber, and antioxidants for corticosteroid sparing in ulcerative colitis: A randomized, controlled trial</atitle><jtitle>Clinical gastroenterology and hepatology</jtitle><addtitle>Clin Gastroenterol Hepatol</addtitle><date>2005-04-01</date><risdate>2005</risdate><volume>3</volume><issue>4</issue><spage>358</spage><epage>369</epage><pages>358-369</pages><issn>1542-3565</issn><eissn>1542-7714</eissn><abstract>Background & Aims
: N-3 fatty acids from fish oil, antioxidants, and short-chain fatty acids (SCFAs) produced during the fermentation of soluble fiber may attenuate inflammation associated with ulcerative colitis (UC). We assessed the efficacy of a nutritionally balanced oral supplement enriched with fish oil, fructooligosaccharides, gum arabic, vitamin E, vitamin C, and selenium on disease activity and medication use in adults with mild to moderate UC.
Methods
: A total of 121 patients with UC and a disease activity index (DAI) from 3–9 on a 12-point scale were block randomized for extent of disease and smoking status. In addition to their usual diet, patients consumed 18 oz of the oral supplement or a carbohydrate-based placebo formula each day for 6 months. Clinical and histologic responses were assessed at 3 and 6 months or at the final visit. A change in average prednisone use between groups was tested by using a linear mixed-effects model.
Results
: Eighty-six patients completed the study. Baseline characteristics were not different between groups except for a higher total DAI score in the oral supplement group (7.3 ± 1.3; n = 36) compared with the placebo group (6.2 ± 2.0; n = 50) (
P < .05). Both groups showed significant and similar degree of improvement at 6 months in DAI (−2.5 for oral supplement and −2.8 for placebo) and histologic index (−1.9 for oral supplement vs. −2.0 for placebo). Both intent-to-treat and completed patients given oral supplement had a significantly greater rate of decrease in the dose of prednisone required to control clinical symptoms over 6 months as compared with the placebo group (
P < .001).
Conclusions
: The improvement in clinical response combined with a decreased requirement for corticosteroids suggest that this enriched oral supplement can be a useful adjuvant therapy in patients with UC.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>15822041</pmid><doi>10.1016/S1542-3565(04)00672-X</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1542-3565 |
ispartof | Clinical gastroenterology and hepatology, 2005-04, Vol.3 (4), p.358-369 |
issn | 1542-3565 1542-7714 |
language | eng |
recordid | cdi_proquest_miscellaneous_67721779 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | Administration, Oral Adrenal Cortex Hormones - administration & dosage Adult Antioxidants - therapeutic use Biopsy, Needle Colitis, Ulcerative - diet therapy Colitis, Ulcerative - pathology Dietary Fiber - administration & dosage Dietary Supplements Double-Blind Method Female Fish Oils - therapeutic use Follow-Up Studies Humans Immunohistochemistry Intestinal Mucosa - pathology Male Middle Aged Monitoring, Physiologic Probability Reference Values Risk Assessment Statistics, Nonparametric Treatment Outcome |
title | An oral supplement enriched with fish oil, soluble fiber, and antioxidants for corticosteroid sparing in ulcerative colitis: A randomized, controlled trial |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T23%3A01%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=An%20oral%20supplement%20enriched%20with%20fish%20oil,%20soluble%20fiber,%20and%20antioxidants%20for%20corticosteroid%20sparing%20in%20ulcerative%20colitis:%20A%20randomized,%20controlled%20trial&rft.jtitle=Clinical%20gastroenterology%20and%20hepatology&rft.au=Seidner,%20Douglas%20L.&rft.aucorp=The%20Enteral%20Nutrition%20in%20Ulcerative%20Colitis%20Study%20Group&rft.date=2005-04-01&rft.volume=3&rft.issue=4&rft.spage=358&rft.epage=369&rft.pages=358-369&rft.issn=1542-3565&rft.eissn=1542-7714&rft_id=info:doi/10.1016/S1542-3565(04)00672-X&rft_dat=%3Cproquest_cross%3E67721779%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67721779&rft_id=info:pmid/15822041&rft_els_id=S154235650400672X&rfr_iscdi=true |